CT-P51

Phase 3Small molecule

CCelltrion

CT-P51 is one of 34 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Squamous Non-Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 3

Active, not recruiting

Non-Squamous Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

CT-P51

CCelltrion

Phase 3

1 2

Tecentriq

Roche

Preclinical

9 3

Libtayo

Regeneron

Preclinical

3 4

Vizimpro

Pfizer

Preclinical

3 5

Folvite

Xylocaine

2 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 8

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 9

Rilotumumab

Amgen

Preclinical

2 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Non-Squamous Non-Small Cell Lung Cancer

NCT06939595

Clinical

Trials by Indication[1]

Non-Squamous Non-Small Cell Lung Cancer1 trial

A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting·CCelltrion·Phase 3·NCT06939595·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CT-P51. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT-P51 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT-P51. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celltrion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCelltrion

CT-P51

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Non-Squamous Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News